Startups

Takeda Pharmaceutical Company Limited logo

Takeda Pharmaceutical Company Limited

Tokyo, Japan · Osaka, Japan · Cambridge, Massachusetts, United States

takeda.com

Japanese public biopharmaceutical parent company founded as Chobei Takeda’s Osaka medicine business in 1781 and incorporated in 1925. Takeda has its global headquarters in Tokyo and a global research and business hub in Cambridge, Massachusetts, and manufacturing and research operations in Osaka. Its research and commercial work spans gastrointestinal and inflammatory diseases, neuroscience, oncology, plasma-derived therapies and vaccines. It integrates data, digital technologies and artificial intelligence into discovery and operations, including work with MIT. Its neuroscience business includes orexin-pathway research: the FDA approved Orzeyful (oveporexton) for adults with narcolepsy type 1 on 5 August 2026; approval and subsequent launch or controlled-substance scheduling are distinct. Julie Kim became President and CEO on 24 June 2026. The current public directory lists 16 executives and 11 directors, comprising 24 distinct people. This profile represents the parent corporation and its direct equity investments, including the historical $60M Wave Life Sciences subscription closed in April 2018, separately from commercial collaboration payments and the independently tracked Takeda Ventures entities.

Founded 1781

Team

Andrew S. PlumpAndrew S. PlumpPresident, Research & Development · Director
Asuka MiyabashiraAsuka MiyabashiraPresident, Japan Pharma Business Unit and Japan Country Head
Awny FarajallahAwny FarajallahChief Medical Officer
Bruce BroussardBruce BroussardExternal Director – Audit & Supervisory Committee member
Elaine ShannonElaine ShannonPresident, Global Supply & Quality
Gabriele RicciGabriele RicciChief Data & Technology Officer
Giles PlatfordGiles PlatfordPresident, International Business Unit
Jennifer SmoterJennifer SmoterChief Communications & Governance Officer
John MaraganoreJohn MaraganoreExternal Director
Julie KimJulie KimPresident and CEO · Representative Director
Kimberly A. ReedKimberly A. ReedExternal Director - Audit & Supervisory Committee member
Koichiro KimuraKoichiro KimuraExternal Director – Head of the Audit & Supervisory Committee
Lauren DupreyLauren DupreyChief Transformation Officer
Marcello AgostiMarcello AgostiInterim Head, Strategy & Portfolio Development
Masami IijimaMasami IijimaExternal Director - Chair of the Board meeting
Miki TsusakaMiki TsusakaExternal Director
Milano FurutaMilano FurutaChief Financial Officer · Director
Natalie FurneyNatalie FurneyGlobal General Counsel
Nicola GreenwayNicola GreenwayChief Human Resources Officer
Paul StoffelsPaul StoffelsExternal Director
Ramy RiadRamy RiadPresident, Plasma-Derived Therapies Business Unit
Rhonda PachecoRhonda PachecoPresident, U.S. Business Unit and U.S. Country Head
Steven GillisSteven GillisExternal Director
Teresa BitettiTeresa BitettiPresident, Global Oncology Business Unit

Investments